Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2008-09-12 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2008-09-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce specific events or changes. The content includes information about the approval of a stock option certificate under a new incentive plan and references a proxy statement filed earlier. It does not contain financial statements or detailed financial performance data. The key event reported is related to management compensation arrangements and stock option plans, which is typically covered under management or board changes or compensation disclosures. However, since it is a Form 8-K reporting a compensatory arrangement and referencing a proxy statement, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement rather than a full report or detailed compensation report (DEF 14A). The document length is short and it is a standalone filing reporting a specific event, not a full report or presentation.
2008-09-10 English
FORM 4
Director's Dealing
2008-09-08 English
FORM 4
Director's Dealing
2008-09-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated July 31, 2008. It specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release announcing quarterly highlights is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 2462 characters, which is relatively short and consistent with a report announcing results rather than the full earnings release. According to the rules, an initial announcement of quarterly financial results (key highlights only) corresponds to an Earnings Release (ER). The presence of a press release announcing quarterly highlights aligns with the ER category rather than a full interim report or regulatory filing. Therefore, the document should be classified as an Earnings Release (ER).
2008-08-05 English
FORM 3
Director's Dealing
2008-07-21 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.